| Seagen Inc (SGEN) | |||
|---|---|---|---|
| 228.74 -0.16 (-0.07%) | 12-13 16:00 | ||
| Open: | 228.93 | Pre. Close: | 228.9 |
| High: | 228.96 | Low: | 228.74 |
| Volume: | 19,392,808 | Market Cap: | 43,155(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 267.43 One year: 312.35 |
| Support: | Support1: 218.34 Support2: 211.77 |
| Resistance: | Resistance1: 228.96 Resistance2: 267.43 |
| Pivot: | 224.17  |
| Moving Averages: | MA(5): 228.74 MA(20): 221.53 MA(100): 210.94 MA(250): 192.54 |
| MACD: | MACD(12,26): 4.12  Signal(12,26,9): 3.46 |
| %K %D: | %K(14,3): 98.67 %D(3): 98.67 |
| RSI: | RSI(14): 82.92 |
| 52-Week: | High: 228.96 Low: 126.47 Change(%): 80.1 |
| Average Vol(K): | 3-Month: 1630 10-Days: 3377 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 229.273 - 230.402 | 230.402 - 231.318 |
| Low: | 225.538 - 227.113 | 227.113 - 228.39 |
| Close: | 226.56 - 228.917 | 228.917 - 230.828 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SGEN ] has closed below upper band by 30.6%. Bollinger Bands are 149.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 188.66 |
| Shares Float (M) | 129.83 |
| % Held by Insiders | 0.81 |
| % Held by Institutions | 88.83 |
| Shares Short (K) | 9580 |
| Shares Short Prior Month (K) | 10420 |
| Stock Financials | |
|---|---|
| EPS | -4.000 |
| Book Value (p.s.) | 13.520 |
| Profit Margin | -32.61 |
| Operating Margin | -35.20 |
| Return on Assets (ttm) | -12.9 |
| Return on Equity (ttm) | -27.9 |
| Qtrly Rev. Growth | 27.1 |
| Gross Profit (p.s.) | 1.102 |
| Sales Per Share | 12.191 |
| EBITDA (p.s.) | -3.590 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -540.15 |
| Levered Free Cash Flow (M) | -277.09 |
| Stock Valuation | |
|---|---|
| PE Ratio | -57.19 |
| PEG Ratio | 0.55 |
| Price to Book value | 16.92 |
| Price to Sales | 18.76 |
| Price to Cash Flow | -79.89 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
